1 hour ago
1
James Brumley, The Motley Fool
Mon, April 27, 2026 astatine 11:00 AM CDT 4 min read
Investors had each crushed to fishy today's quality from Sagimet Biosciences (NASDAQ: SGMT) was coming sooner oregon later. Nevertheless, seeing the authoritative announcement has intelligibly proven inspiring. As of 11:40 a.m. ET Monday, SGMT shares are up a hefty 45.2%, reaching a precocious past seen successful November.
The news? Following a palmy Phase 3 proceedings successful China, the biopharma institution present plans to initiate Phase 3 trials of its acne-fighting denifanstat successful the United States.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected a little-known company, called an "Indispensable Monopoly," providing the captious exertion Nvidia and Intel some need. Continue »
It's not the lone cause successful Sagimet's pipeline, for the record. Its TVB-3567 is besides successful Phase 1 trials arsenic an acne treatment, arsenic good arsenic presently successful preclinical studies arsenic a attraction for coagulated tumors. Denifanstat besides precocious ended Phase 1 investigating arsenic a combo therapy for metabolic dysfunction associated steatohepatitis (MASH), with Phase 2 trials for this intent expected to beryllium acceptable successful the second fractional of this year.
The main operator of Monday's bullishness, however, is the determination to determination guardant with the improvement of denifanstat arsenic a attraction for mean to terrible acne wrong the United States. And soon. Following the occurrence of the company's home Phase 2 investigating of the cause arsenic good arsenic the efficacy demonstrated by developmental spouse Ascletis Bioscience's Phase 3 trials performed successful China, Sagimet Biosciences plans connected launching a Phase 3 proceedings successful the U.S. sometime successful the 2nd fractional of 2026.
Up for grabs is simply a marketplace of 10 cardinal acne suffers successful the U.S. alone, though it's surely acold bigger beyond the United States' border. Healthcare manufacture probe outfit Towards Healthcare estimates the planetary acne attraction marketplace is worthy astir $11 cardinal per twelvemonth now, but could turn to astir $17 cardinal by 2034.
The quality is understandably exciting, but there's a corresponding downside. That is, Sagimet Biosciences is besides readying to rise $175 cardinal by issuing implicit 29 cardinal caller shares of the institution astatine $6.00 per share, dramatically diluting the 32 cardinal shares already issued and outstanding. For much perspective, earlier today's surge, SGMT stock's terms of $5.86 translated into a marketplace headdress of conscionable nether $190 million. Raising this superior -- mostly to money denifanstat's adjacent signifier of investigating -- is taking a measurable toll connected the worth of some existent and aboriginal shareholders' stakes.
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·